MA32226B1 - Compositions et leurs procedes de preparation et d'utilisation - Google Patents

Compositions et leurs procedes de preparation et d'utilisation

Info

Publication number
MA32226B1
MA32226B1 MA33245A MA33245A MA32226B1 MA 32226 B1 MA32226 B1 MA 32226B1 MA 33245 A MA33245 A MA 33245A MA 33245 A MA33245 A MA 33245A MA 32226 B1 MA32226 B1 MA 32226B1
Authority
MA
Morocco
Prior art keywords
compositions
methods
preparation
administering
treating
Prior art date
Application number
MA33245A
Other languages
Arabic (ar)
English (en)
Inventor
Barry D Quart
Colin Edward Rowlings
Original Assignee
Ardea Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2008/071392 external-priority patent/WO2009018233A1/fr
Application filed by Ardea Biosciences Inc filed Critical Ardea Biosciences Inc
Publication of MA32226B1 publication Critical patent/MA32226B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La présente invention concerne des compositions, leurs procédés de préparation et des procédés de traitement ou de prévention de maladies, comprenant l'administration des compositions.
MA33245A 2008-04-14 2010-10-14 Compositions et leurs procedes de preparation et d'utilisation MA32226B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US4488608P 2008-04-14 2008-04-14
PCT/US2008/071392 WO2009018233A1 (fr) 2007-07-30 2008-07-28 Dérivés de n-(arylamino)arylsulfonamide comprenant des polymorphes en tant qu'inhibiteurs de mek ainsi que compositions, procédés d'utilisation et procédés de préparation de ceux-ci
US15977809P 2009-03-12 2009-03-12
PCT/US2009/040538 WO2009129246A2 (fr) 2008-04-14 2009-04-14 Compositions et leurs procédés de préparation et d'utilisation

Publications (1)

Publication Number Publication Date
MA32226B1 true MA32226B1 (fr) 2011-04-01

Family

ID=41199689

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33245A MA32226B1 (fr) 2008-04-14 2010-10-14 Compositions et leurs procedes de preparation et d'utilisation

Country Status (20)

Country Link
US (1) US8808742B2 (fr)
EP (1) EP2291350A4 (fr)
JP (1) JP2011518786A (fr)
KR (1) KR20110014149A (fr)
CN (1) CN102131771A (fr)
AU (1) AU2009236325A1 (fr)
BR (1) BRPI0911297A2 (fr)
CA (1) CA2720671A1 (fr)
CO (1) CO6331425A2 (fr)
CR (1) CR11731A (fr)
CU (1) CU20100200A7 (fr)
DO (1) DOP2010000304A (fr)
EA (1) EA201001639A1 (fr)
EC (1) ECSP10010548A (fr)
IL (1) IL208284A0 (fr)
MA (1) MA32226B1 (fr)
MX (1) MX2010011314A (fr)
SG (1) SG189784A1 (fr)
WO (1) WO2009129246A2 (fr)
ZA (1) ZA201006944B (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602005013990D1 (de) 2004-09-17 2009-05-28 Eisai R&D Man Co Ltd Medizinische zusammensetzung mit verbesserter stabilität und reduzierten gelierungseigenschaften
EP2281901B1 (fr) 2005-08-02 2013-11-27 Eisai R&D Management Co., Ltd. Composition pharmaceutique anti-tumeur avec des inhibiteurs d'angiogénèse
WO2007136103A1 (fr) 2006-05-18 2007-11-29 Eisai R & D Management Co., Ltd. Agent antitumoral destiné au cancer de la thyroïde
TWI524890B (zh) * 2009-07-24 2016-03-11 亞德生化公司 （ｒ）－ｎ－（３，４－二氟－２－（２－氟－４－碘苯胺基）－６－甲氧基苯基）－１－（２，３－二羥丙基）環丙烷－１－磺醯胺及（ｓ）－ｎ－（３，４－二氟－２－（２－氟－４－碘苯胺基）－６－甲氧基苯基）－１－（２，３－二羥丙基）環丙烷－１－磺醯胺之製備
CA2814617C (fr) * 2009-10-13 2017-12-19 Allostem Therapeutics Llc Nouveaux inhibiteurs de mek, utiles dans le traitement des maladies
AU2011240003A1 (en) * 2010-04-16 2012-11-08 Bayer Intellectual Property Gmbh Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations
ES2705950T3 (es) 2011-06-03 2019-03-27 Eisai R&D Man Co Ltd Biomarcadores para predecir y valorar la capacidad de respuesta de sujetos con cáncer de tiroides y de riñón a compuestos de lenvatinib
TWI653041B (zh) 2012-06-04 2019-03-11 美商製藥有限責任公司 布魯頓氏酪胺酸激酶抑制劑之結晶形式
CN103570594A (zh) * 2012-08-01 2014-02-12 苏州迈泰生物技术有限公司 二芳基胺类化合物及其在制备抗恶性肿瘤药物中的用途
US20150265679A1 (en) 2012-11-02 2015-09-24 The United States Of America, As Represented By Secretary, Department Of Health And Human Services Method of reducing adverse effects in a cancer patient undregoing treatment with a mek inhibitor
JPWO2014098176A1 (ja) 2012-12-21 2017-01-12 エーザイ・アール・アンド・ディー・マネジメント株式会社 キノリン誘導体のアモルファス及びその製造方法
KR102204279B1 (ko) 2013-05-14 2021-01-15 에자이 알앤드디 매니지먼트 가부시키가이샤 자궁내막암 대상의 렌바티닙 화합물에 대한 반응성을 예측 및 평가하기 위한 생체표지
EP2848246A1 (fr) 2013-09-13 2015-03-18 Bayer Pharma Aktiengesellschaft Compositions pharmaceutiques contenant du refametinib
PL3043778T3 (pl) * 2013-09-13 2018-04-30 Bayer Pharma Aktiengesellschaft Kompozycje farmaceutyczne zawierające refametinib
WO2015196072A2 (fr) 2014-06-19 2015-12-23 Whitehead Institute For Biomedical Research Utilisations d'inhibiteurs de kinase pour l'induction et le maintien de la pluripotence
EP3193877A4 (fr) 2014-08-07 2018-04-04 Pharmacyclics LLC Nouvelles formulations d'un inhibiteur de la tyrosine kinase de bruton
EP4089076A1 (fr) 2014-08-28 2022-11-16 Eisai R&D Management Co., Ltd. Dérivé de quinoline à pureté élevée et son procédé de fabrication
ES2967362T3 (es) 2015-02-25 2024-04-29 Eisai R&D Man Co Ltd Método para suprimir el amargor de un derivado de quinolina
IL315294A (en) 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of proton tyrosine kinase inhibitor
CA2978226A1 (fr) 2015-03-04 2016-09-09 Merck Sharpe & Dohme Corp. Association d'un antagoniste de pd-1 et d'un inhibiteur des tyrosines kinases vegfr/fgfr/ret pour traiter le cancer
US11369623B2 (en) 2015-06-16 2022-06-28 Prism Pharma Co., Ltd. Anticancer combination of a CBP/catenin inhibitor and an immune checkpoint inhibitor
EP3341739A4 (fr) * 2015-08-28 2019-07-10 BioIncept LLC Peptides mutants et procédés de traitement de sujets les employant
AU2016317574A1 (en) 2015-08-28 2018-03-29 Bioincept, Llc Compositions and methods for the treatment of neurodamage
WO2018189311A1 (fr) * 2017-04-13 2018-10-18 Jean Paul Remon Compositions à base de xanthohumol
US20220143049A1 (en) 2019-03-21 2022-05-12 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
US20220401436A1 (en) 2019-11-08 2022-12-22 INSERM (Institute National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (fr) 2020-01-22 2021-07-29 Onxeo Nouvelle molécule dbait et son utilisation
CN113476476A (zh) * 2021-08-25 2021-10-08 娜布其 一种治疗白癜风疾病的药物及其制作工艺

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8005A (en) * 1851-04-01 He ne y bo o t
US5162117A (en) 1991-11-22 1992-11-10 Schering Corporation Controlled release flutamide composition
SK9822001A3 (en) * 1999-01-13 2002-08-06 Warner Lambert Co 1-heterocycle substituted diarylamines, pharmaceutical compositions based thereon and their use in therapy
MX2008002114A (es) 2005-07-21 2008-04-17 Ardea Biosciences Inc Inhibidores de n-(arilamino)-sulfonamida de mek.
US8101799B2 (en) * 2005-07-21 2012-01-24 Ardea Biosciences Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
WO2009018238A1 (fr) * 2007-07-30 2009-02-05 Ardea Biosciences, Inc. Combinaisons d'inhibiteurs de mek et d'inhibiteurs de raf kinase et leurs utilisations
US7842836B2 (en) 2006-04-11 2010-11-30 Ardea Biosciences N-aryl-N'alkyl sulfamides as MEK inhibitors
KR20140098185A (ko) * 2007-07-30 2014-08-07 아디아 바이오사이언스즈 인크. 다형체를 포함하는, ｍｅｋ의 억제제로서의 ｎ-(아릴아미노) 술폰아미드의 유도체 및 조성물, 사용 방법 및 이의 제조 방법
US8044240B2 (en) * 2008-03-06 2011-10-25 Ardea Biosciences Inc. Polymorphic form of N-(S)-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide and uses thereof

Also Published As

Publication number Publication date
KR20110014149A (ko) 2011-02-10
CR11731A (es) 2011-06-08
EP2291350A2 (fr) 2011-03-09
EA201001639A1 (ru) 2011-06-30
EP2291350A4 (fr) 2012-09-19
AU2009236325A1 (en) 2009-10-22
DOP2010000304A (es) 2011-10-15
CU23904B1 (fr) 2013-06-28
ZA201006944B (en) 2015-06-24
SG189784A1 (en) 2013-05-31
IL208284A0 (en) 2010-12-30
CA2720671A1 (fr) 2009-10-22
MX2010011314A (es) 2010-11-12
CO6331425A2 (es) 2011-10-20
US20110033539A1 (en) 2011-02-10
JP2011518786A (ja) 2011-06-30
WO2009129246A3 (fr) 2011-03-31
BRPI0911297A2 (pt) 2019-09-24
CU20100200A7 (es) 2011-11-15
US8808742B2 (en) 2014-08-19
CN102131771A (zh) 2011-07-20
WO2009129246A2 (fr) 2009-10-22
ECSP10010548A (es) 2010-11-30

Similar Documents

Publication Publication Date Title
MA32226B1 (fr) Compositions et leurs procedes de preparation et d'utilisation
MA30914B1 (fr) Dihydropyrazolones substituees utilisees dans le traitement de maladies cardiovasculaires et hematologiques.
MA34765B1 (fr) Antagonistes des récepteurs de l'acide lysophosphatidique et utilisations de ceux-ci
LTPA2017009I1 (lt) Brutono tirozinkinazės inhibitoriai
CY1118984T1 (el) Παρασκευη ενεργων, ακρως φωσφορυλιωμενων, ανθρωπινων λυσοσωμικων ενζυμων σουλφατασης και χρησεις αυτων
MA33123B1 (fr) 2-acetamido-5-aryl-1,2,4-triazolones substitues et leur utilisation
MA31433B1 (fr) Inhibiteurs de la p70 s6 kinase
MA34169B1 (fr) Dérivés d'acide 1-amino-2-cyclopropyléthylboronique
MA34655B1 (fr) Dérivés de 2,3- dihydroimidazo[1,2-c]quinazoléine substitués par un aminoalcool utiles pour traiter des troubles hyperprolifératifs et des maladies associées à l'angiogenèse
TR200103233T2 (tr) Antikolinerjik etkili bileşik ve ß-mimetikler bazında yeni ilaç bileşimleri.
MA37742B1 (fr) Dérivés d'oestra-1,3,5 (10), 16-tétraène substitués en position 3, leurs procédés de préparation, préparations pharmaceutiques les contenant, et leur utilisation pour la fabrication de médicaments
EA201270666A1 (ru) Соединения и фармацевтические композиции для снижения уровня мочевой кислоты
MA31245B1 (fr) Amides de 4-aryl-1,4-dihydro-1,6-naphthyridine substitués et utilisation de ceux-ci
MA33608B1 (fr) Composition pharmaceutique, forme galenique, procede pour leur preparation, methodes de traitement et leurs utilisations
MA32230B1 (fr) Formes cristallines et deux formes solvatées de lactates de 4-amino-5-fluoro -3-[5-(4-méthylpipérazin-1-yl)-1h-benzimidazol-2-yl]quinolin-2(1h)-one
MA31502B1 (fr) Anticorps anti-notch 1 specifiques a nrr et ses procedes d'utilisation
GEP20125565B (en) Lactam compounds and their pharmaceutical use
MA32876B1 (fr) Anticorps dirigés contre l'angiopoïétine 2 humaine
MA34019B1 (fr) Aryltriazolone liée à un bis-aryle et son utilisation
MA39033A1 (fr) Formes solides d'acide {[5-(3-chlorophényl)-3-hydroxypyridine-2-carbonyl] amino}acétique, compositions et leurs utilisations
MY143795A (en) Tetrahydropyridoindole derivatives
MA47356A1 (fr) Dérivés d'isochromène utiles en tant qu'inhibiteurs des phosphoinositide 3-kinases
MA33419B1 (fr) Composés et compositions pour le traitement de maladies parasitaires
MX2009007337A (es) Indazoles sustituidos con 5-piridinona.
MA30041B1 (fr) Immunoglobulines